Safety and Tolerability of IRX-101 in Patients Receiving Intravitreal Injections

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

240

Participants

Timeline

Start Date

December 31, 2025

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Retinal Disease

Interventions

DRUG

IRX-101

IRX-101 is a novel ocular anti-septic

DRUG

Providone-Iodine

5% Providone-Iodine

Trial Locations (1)

R. Gary Lane, II MD, San Antonio

All Listed Sponsors

lead

iRenix Medical, Inc.

INDUSTRY